Tweet
Hi All,
New treatment delivery methods such as depots and emulsions have the potential to eradicate patient compliance issues with eye drops while delivering a steady dose of sustained medication.
One drug that may improve compliance by removing patient responsibility altogether is Dextenza from Ocular Therapeutix. Dextenza is administered by a physician as a bioresorbable intracanalicular depot for release of dexamethasone to the ocular surface for up to 30 days, according to a company press release.
DEXTENZA is a corticosteroid intracanalicular insert placed through the punctum, a natural opening in the eye lid, into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA is intended to resorb and exit the nasolacrimal system without the need for removal.
DEXTENZA has completed Phase 3 evaluation for the treatment of ocular pain and inflammation following ophthalmic surgery. DEXTENZA is also being studied for allergic conjunctivitis.
USA Only.
http://www.ocutx.com/research/dextenza/
New treatment delivery methods such as depots and emulsions have the potential to eradicate patient compliance issues with eye drops while delivering a steady dose of sustained medication.
One drug that may improve compliance by removing patient responsibility altogether is Dextenza from Ocular Therapeutix. Dextenza is administered by a physician as a bioresorbable intracanalicular depot for release of dexamethasone to the ocular surface for up to 30 days, according to a company press release.
DEXTENZA is a corticosteroid intracanalicular insert placed through the punctum, a natural opening in the eye lid, into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA is intended to resorb and exit the nasolacrimal system without the need for removal.
DEXTENZA has completed Phase 3 evaluation for the treatment of ocular pain and inflammation following ophthalmic surgery. DEXTENZA is also being studied for allergic conjunctivitis.
USA Only.
http://www.ocutx.com/research/dextenza/